Drug Trial Radar · NCT04538625
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
287
Actual
Start
Oct 7, 2020
Primary completion
Aug 7, 2023
Study completion Oct 30, 2023
Sponsor
- Lead sponsor
- Napo Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 24-week, (two 12-week stages), randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors treated with targeted cancer therapy-containing treatment regimens. Diarrhea grading will be done according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Patients will be randomized 1:1 to placebo or crofelemer and will be stratified by the type of targeted cancer therapy and the tumor type. Placebo and/or crofelemer will be dispensed at Visit 1/Day 1 with the concurrent start of the targeted cancer therapy regimen. The initial Stage I double-blind placebo-controlled primary treatment phase will occur over a 12-week period to accommodate approximately 3 cycle chemotherapy cancer treatment dosing-cycles. The Primary and Secondary Endpoints will be analyzed after the last patient last visit (LPLV) of Stage I. After completing the Stage I double-blind, placebo-controlled primary treatment phase, the subjects will have the option to remain on their assigned treatment arm and reconsented to enter into the Stage II extension phase. Reconsent will be required to enter into Stage II. For subjects who do not reconsent, visit 5 will be the last study visit.
Conditions
- Cancer Therapy-Related Diarrhea
- Chemotherapy-related Diarrhea
- Adult Solid Tumor
- Prophylaxis of Diarrhea
- Symptomatic Relief of Diarrhea
- Targeted Therapy-related Diarrhea
Interventions
Crofelemer 125 MG [Mytesi]Drug
Randomized, Double-blind, Placebo-controlled, two arm trial
PlaceboDrug
Matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Number of Loose/watery StoolsTime frame: For the entire 12-week double-blind placebo-controlled treatment period (The Stage 1 Primary Treatment Phase).
Locations
52 sites in 5 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates PC - HAL
Prescott, Arizona
Pacific Cancer Medical Center Inc
Anaheim, California
The Oncology Institute of Hope and Innovation
Corona, California
The Oncology Institute of Hope and Innovation
Glendale, California
PIH Health Whittier Hospital
Whittier, California
SCL Health Research Institute
Lafayette, Colorado
GenesisCare USA
Aventura, Florida
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida
BRCR Global
Plantation, Florida
Advanced Research Institute
St. Petersburg, Florida
American Oncology Partners of Maryland
Bethesda, Maryland
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota
Nebraska Methodist Hospital
Omaha, Nebraska
North Shore Hematology Oncology Associates dba New York Cancer and Blood Specialists
Port Jefferson Station, New York
Jacobi Medical Center
The Bronx, New York
Gabrail Cancer Research
Canton, Ohio
Oregon Health & Science University (OHSU) Knight Cancer Institute
Portland, Oregon
The West Clinic Research
Germantown, Tennessee
Texas Oncology - Denison
Denison, Texas
Texas Oncology, P.A. - Flower Mound
Flower Mound, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology - New Braunfels
New Braunfels, Texas
Texas Oncology - Plano East
Plano, Texas
Texas Oncology - Gulf Coast
Webster, Texas
Inova Schar Cancer Institute
Fairfax, Virginia
Shenandoah Oncology Associates
Winchester, Virginia
MultiCare Institute for Research and Innovation
Tacoma, Washington
Fleischer Medical Center
Buenos Aires, Argentina
Medical Center Austral
Buenos Aires, Argentina
Buenos Aires British Hospital
Buenos Aires, Argentina
Cordoba Oncology Institute (IONC)
Córdoba, Argentina
Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)
Paraná, Argentina
CEDIT Diagnostic and Treatment Center
Salta, Argentina
9 of July Sanatorium
San Miguel de Tucumán, Argentina
Isis Specialized Clinic
Santa Fe, Argentina
LLC "Todua Clinic"
Tbilisi, Georgia
Archangel St. Michael Multiprofile Clinical Hospital LTD
Tbilisi, Georgia
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
Tbilisi, Georgia
LTD Caucasus Medical Centre
Tbilisi, Georgia
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.